Helen K. Angell
Oncology R&D, AstraZeneca
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer.
Journal: Molecular cancer
Published: June 25, 2025
Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High CST2 Expression and a Favorable Prognosis.
Journal: Cancer research communications
Published: March 14, 2025
AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 12, 2024
Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring.
Journal: Frontiers in immunology
Published: April 23, 2024
Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma.
Journal: Cancer research communications
Published: April 12, 2023
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 02, 2023
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
Journal: Oncoimmunology
Published: June 27, 2022
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Journal: British journal of cancer
Published: March 31, 2021
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.
Journal: Nature reviews. Cancer
Published: June 22, 2020
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
Journal: British journal of cancer
Published: May 01, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Journal: The Lancet. Oncology
Published: February 28, 2020
The Immunoscore: Colon Cancer and Beyond.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 17, 2019
Last Updated: 09/26/2026